<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337752</url>
  </required_header>
  <id_info>
    <org_study_id>CBHQ880A2203</org_study_id>
    <secondary_id>2009-010875-26</secondary_id>
    <nct_id>NCT01337752</nct_id>
  </id_info>
  <brief_title>Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study will evaluate the effects of BHQ880 in patients with previously untreated multiple
      myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy.
      The primary objective of the study will be to evaluate the effect of BHQ880 in combination
      with bortezomib and dexamethasone, compared to placebo administered with the combination on
      the time to first Skeletal Related Event (SRE) on study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone</measure>
    <time_frame>18-month median time to first SRE assumed for the placebo arm</time_frame>
    <description>Time to first SRE from randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of BHQ880 in combination with bortezomib and dexamethasone</measure>
    <time_frame>From screening through month 17</time_frame>
    <description>Number of patients with adverse events/serious adverse events, abnormal clinical laboratory values, and the assessment of immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the PharmacoKinetics (PK) profiles of BHQ880 and bortezomib</measure>
    <time_frame>At screening and weeks 1, 2, 4, 7, 10, 11, 13, 16, 25 and 34</time_frame>
    <description>Determine the pharmacokinetic parameters for BHQ880 and bortezomib (Cmax, Tmax, AUC0-tlast, t1/2, and accumulation ratio of BHQ880).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of BHQ880 on bone metabolism</measure>
    <time_frame>At screening and at months 3, 6, 12, and 18</time_frame>
    <description>1) Change in bone mineral density, measured by dual-emission X-ray absorptiometry (DXA), from randomization to 12 and 18 months; 2) Change in bone strength, measured by quantitative computed tomography (qCT), from randomization to 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the antimyeloma effect of BHQ880 compared to placebo when used in combination with bortezomib and dexamethasone.</measure>
    <time_frame>From the first dose of study medication through month 17</time_frame>
    <description>1) The overall response rate (partial response plus complete response); 2) Progression-free survival following initiation of BHQ880</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>BHQ880</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BHQ880 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHQ880</intervention_name>
    <arm_group_label>BHQ880</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHQ990</intervention_name>
    <arm_group_label>BHQ880 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of multiple myeloma

          2. Life expectancy of more than 6 months in the absence of intervention

          3. Must not have received previous or be receiving current antimyeloma therapies

          4. Renal insufficiency

          5. Recovered from the effects of any prior surgery or radiotherapy

        Exclusion Criteria:

          1. Prior IV bisphosphonate therapy at any time or oral bisphosphonate therapy within 4
             months of study entry

          2. Paget's disease of bone or uncorrected hyperparathyroidism

          3. Impaired cardiac function

          4. Known HIV, known active hepatitis B, or known or suspected hepatitis C infection

          5. Pregnant or nursing (lactating) women,

          6. Women of child-bearing potential, UNLESS agreeable to using 2 birth control methods

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Chicago Hospital Dept. of Univ of Chicago (2)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=11143</url>
    <description>Results for CBHQ880A2203 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>renal insufficiency</keyword>
  <keyword>untreated multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

